Trial Profile
An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration [EXTENSION OF 700238595]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Registrational
- Sponsors Regeneron Pharmaceuticals
- 20 Mar 2014 New trial record